A novel natural PPARγ agonist, Gypenoside LXXV, ameliorates cognitive deficits by enhancing brain glucose uptake via the activation of Akt/GLUT4 signaling in db/db mice
- 22 February 2022
- journal article
- research article
- Published by Wiley in Phytotherapy Research
- Vol. 36 (4) , 1770-1784
Abstract
Targeting the PPARγ might be a potential therapeutic strategy for diabetes‐associated cognitive decline (DACD). In this study, Gypenoside LXXV (GP‐75), a dammarane‐type triterpene compound isolated from Gynostemma pentaphyllum, was found to be a novel PPARγ agonist using a dual‐luciferase reporter assay system. However, whether GP‐75 has protective effects against DACD remains unknown. Interestingly, intragastric administration of GP‐75 (40 mg/kg/day) for 12 weeks significantly attenuated the cognitive deficit in db/db mice. GP‐75 treatment significantly improved the glucose tolerance and lipid metabolism, and suppressed neuroinflammation. Notably, GP‐75 treatment dramatically increased the uptake of glucose by the brain, as detected by 18F‐FDG PET. Incubation of primary cortical neurons with GP‐75 significantly increased 2‐deoxyglucose uptake. In addition, GP‐75 treatment markedly increased the p‐Akt (Ser 473)/total Akt levels and the expression levels of PPARγ and GLUT4, while decreasing the levels of p‐IRS‐1 (Ser 616)/total IRS‐1. Importantly, all of these protective effects mediated by GP‐75 were abolished by cotreatment with the PPARγ antagonist, GW9662. However, GP‐75‐mediated PPARγ upregulation was not affected by coincubation with the phosphatidylinositol 3‐kinase inhibitor, LY294002. Collectively, GP‐75 might be a novel PPARγ agonist that ameliorates cognitive deficit by enhancing brain glucose uptake via the activation of Akt/GLUT4 signaling in db/db mice.Keywords
Funding Information
- China Postdoctoral Science Foundation (2021M702285)
- National Natural Science Foundation of China (81503290, 81772685, 81902522, 81760227, 8170355)
- Natural Science Foundation of Guangdong Province (2018A030310647, 2019A1515010311)
This publication has 41 references indexed in Scilit:
- Brain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrumsNature Reviews Neurology, 2018
- Biochemical and cellular properties of insulin receptor signallingNature Reviews Molecular Cell Biology, 2017
- Enhanced Production of Gypenoside LXXV Using a Novel Ginsenoside-Transforming β-Glucosidase from Ginseng-Cultivating Soil Bacteria and Its Anti-Cancer PropertyMolecules, 2017
- Imbalanced Insulin Actions in Obesity and Type 2 Diabetes: Key Mouse Models of Insulin Signaling PathwayCell Metabolism, 2017
- Gypenoside XVII Enhances Lysosome Biogenesis and Autophagy Flux and Accelerates Autophagic Clearance of Amyloid-β through TFEB ActivationJournal of Alzheimer’s Disease, 2016
- A simple practice guide for dose conversion between animals and humanJournal of Basic and Clinical Pharmacy, 2016
- Attenuation of Aβ25–35-induced parallel autophagic and apoptotic cell death by gypenoside XVII through the estrogen receptor-dependent activation of Nrf2/ARE pathwaysToxicology and Applied Pharmacology, 2014
- Suppression of NADPH oxidase- and mitochondrion-derived superoxide by Notoginsenoside R1 protects against cerebral ischemia–reperfusion injury through estrogen receptor-dependent activation of Akt/Nrf2 pathwaysFree Radical Research, 2014
- Notoginsenoside R1-mediated neuroprotection involves estrogen receptor-dependent crosstalk between Akt and ERK1/2 pathways: A novel mechanism of Nrf2/ARE signaling activationFree Radical Research, 2014
- Gypenoside XLIX, a naturally occurring PPAR-α activator, inhibits cytokine-induced vascular cell adhesion molecule-1 expression and activity in human endothelial cellsEuropean Journal of Pharmacology, 2007